koto_feja
Arcus Biosciences (NYSE:RCUS) traded higher after announcing data for quemliclustat, an investigational therapy co-developed with Gilead (NASDAQ:GILD) from a Phase 1b trial for patients with pancreatic cancer.
Citing a data cut on June 19, 2023, Arcus (RCUS) said that the patients who received the CD73 inhibitor at the 100mg dose indicated a median overall survival of 15.7 months, an improvement compared to those who received chemotherapy alone, the standard of care.
Additional data from a post-hoc analysis suggest that those who received quemliclustat-based regimens showed a 37% reduction in mortality risk and 5.9 months of gain in median overall survival compared to patients who received chemotherapy alone in a synthetic control arm.
The trial named ARC-8 was designed to evaluate quemliclustat plus chemotherapy with or without the anti-PD-1 antibody zimberelimab as a first-line option for metastatic pancreatic ductal adenocarcinoma (mPDAC).
There were no new safety signals in ARC-8. However, there were five deaths, which, according to investigators, were not related to quemliclustat or zimberelimab.
The company plans to share the detailed results from ARC-8 at the ASCO Gastrointestinal Cancer Symposium later this week.
